FUBIMINA : Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ 9-Tetrahydrcannabinol-Like Effects in Mice
暂无分享,去创建一个
B. Thomas | J. Wiley | P. Patel | K. Moore | Megan Grabenauer | Kateland R. Antonazzo | T. Lefever | Ricardo A. Cortes | J. Marusich | Michael T. Wallgren
[1] B. Thomas,et al. Analysis of synthetic cannabinoids using high-resolution mass spectrometry and mass defect filtering: implications for nontargeted screening of designer drugs. , 2012, Analytical chemistry.
[2] M. Damaj,et al. Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor. , 2010, Journal of medicinal chemistry.
[3] I. Vardakou,et al. Spice drugs as a new trend: mode of action, identification and legislation. , 2010, Toxicology letters.
[4] J. Warner,et al. Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice. , 2009, European journal of pharmacology.
[5] T. Tuccinardi,et al. Indoles and related compounds as cannabinoid ligands. , 2008, Mini reviews in medicinal chemistry.
[6] L. Padgett,et al. Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. , 2005, Current medicinal chemistry.
[7] Z. Vogel,et al. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[8] G. Griffin,et al. Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. , 1998, The Journal of pharmacology and experimental therapeutics.
[9] D. R. Compton,et al. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. , 1996, The Journal of pharmacology and experimental therapeutics.
[10] R. L. Barrett,et al. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats , 1995, Neuropharmacology.
[11] P. Soubrié,et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor , 1994, FEBS letters.
[12] K. Rice,et al. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. , 1993, The Journal of pharmacology and experimental therapeutics.
[13] D. Gibson,et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.
[14] L. Gold,et al. Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. , 1992, The Journal of pharmacology and experimental therapeutics.
[15] R. L. Barrett,et al. A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys. , 1992, The Journal of pharmacology and experimental therapeutics.
[16] R. Mechoulam,et al. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs , 1991, Pharmacology Biochemistry and Behavior.
[17] A. Howlett,et al. Determination and characterization of a cannabinoid receptor in rat brain. , 1988, Molecular pharmacology.
[18] R. Mechoulam,et al. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish , 1964 .
[19] Satoru Matsuda,et al. Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products , 2013, Forensic Toxicology.
[20] M. Johnson,et al. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. , 1992, The Journal of pharmacology and experimental therapeutics.